A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria

NCT07545681 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Malaria, Falciparum

Interventions

DRUG: GSK3772701 600 mg
DRUG: GSK3772701 900 mg
DRUG: GSK3772701 150 mg
DRUG: GSK3772701 400 mg
DRUG: GSK3772701 50 mg

Sponsor

GlaxoSmithKline